Floatz logo

MICAFUNGIN

Nutrition Disorders

University of Texas Southwestern Medical CenterSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nutrition Disorders cohort.

Asset / SponsorPhaseRating
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Intralipid
Johane Allard
Phase 4BB
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Lamivudine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB

View all 33 →

Same molecule, other indications

MICAFUNGIN is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
morbid obesityDormant
B
Indicative ·
60 / 100
View asset →
Febrile NeutropeniaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →